Examination about the curative effect of Mirtazapine for the QOL of the pulmonary tumor patient.

Not Applicable

• Conditions: ung cancer and suspected case

• Registration Number: JPRN-UMIN000024726
• Lead Sponsor: Kyoto Prefectural University of Medicine

Brief Summary

The results showed that patients with depression reported a worse quality of life than those without depression. Compared with no medication, the administration of mirtazapine alleviated depressive symptoms. Furthermore, the patients depressive status was affected by their physical symptoms, including coughing, tightness of chest, and dyspnea.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-01
• Study Completion: 2018-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

Not provided

Exclusion Criteria

The patient who could not carry out HADS or was refused. The patient who has a history of the past with hypersensitivity for mirtazapine. The patient with a history of the past with brain disorder (including dementia and Parkinson's disease) of the tissue except the metastasis to brain. The patient with the past of Mental disease medicine treatment except the sleep inducing drug within three months. The patient with severe hepatic dysfunction or renal dysfunction. The patients with the past of suicide consideration or suicide project. The patients who receive medical treatment with heart trouble (myocardial infarction, angina, conduction disorder). The patient with glaucoma or the intraocular pressure sthenia. The patients who receive medical treatment with dysuria. During a pregnant woman, the nursing and the patient who may be pregnant. The patient who takes a monoamine oxidase inhibitor (MAOI) within two weeks. The patient who judged that the examination medical attendant was inappropriate.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of the total Hospital Anxiety and Depression Scale (HADS) score before and after 4 weeks treatment with mirtazapine.

Secondary Outcome Measures

Name	Time	Method
Quick Inventory of Depressive Symptomatology (QIDS-J),Clinical Global Impression of Improvement (CGI).The change of the total HADS score during the observation period in the non-group given mirtazapine. A comparison of HADS in a mirtazapine treatment group and the non-treatment group.